WorkflowClinical Development

Reference · the statutory clock

JCA submission timelines: the 100-day clock, deadline by deadline

Every JCA deadline is measured from a milestone of the EMA's centralised procedure, which is why the 100 days for the dossier is the only one a developer can plan from — and the only one the first four published assessments hit almost exactly. This guide puts each statutory date next to what those assessments actually measured, and shows the clock as Botminds' EU Joint Clinical Assessment runs it.

Updated · 13 min read

See one case, screen by screen →
Watch with transcript →

The JCA submission timelines are a short list of statutory deadlines, almost all of them expressed as a distance from a milestone of the European Medicines Agency's centralised procedure rather than as a fixed date. The one a developer actually plans from is the dossier deadline: 100 days from the Commission's first request, or 60 days in two defined cases. Everything else either depends on a regulatory milestone that can move, or belongs to the assessors. Botminds' EU Joint Clinical Assessment keeps that clock against the work — every question in the scope carries its owner and its next dated step, so the day a comparison decision is late is visible before the result that depends on it is.

Every deadline below is cited to the article that sets it. Every measured figure is read from the procedural tables the four published joint clinical assessment reports print on their own pages. The product screens are the solution's fictional sample assessment.

What the first four assessments measured, end to end

415

days from the first information for the scope to endorsement, for the first report

typical — tovorafenib, 11 March 2025 to 30 April 2026

227

of those days came after the dossier was submitted

typical — tovorafenib, dossier V0.1 to endorsement

167

days from dossier to endorsement in the fastest of the four

typical — tarlatamab, 6 January to 22 June 2026

18

joint clinical assessments initiated between January 2025 and June 2026

typical — European Commission, 9 June 2026

Counted from the dates in each report's own table of procedural steps, and from the Commission's announcement of the first published report. Four assessments is not a trend; it is the entire published record, and the spread inside it is already 60 days.Source: Tovorafenib report; Tarlatamab report; Commission, 9 June 2026

What are the JCA submission timelines?

There are eleven dated obligations in a joint clinical assessment of a medicine, and four of them belong to the developer. The rest belong to the subgroup, the Coordination Group or the Commission, and a developer can neither hurry nor delay them. Reading the list in order is the fastest way to see where a plan can be made and where it cannot.

Every statutory deadline in a joint clinical assessment, with the article that sets it

StepThe deadlineWhere it is writtenWhose it is

StepThe assessment scope is finalised

The deadline≤ 10 days after CHMP adopts its list of questions

Where it is writtenImplementing Regulation, Article 10(2)

Whose it isThe subgroup. In the accelerated and new-indication cases: within 75 days of EMA validating the application.

StepScope explanation meeting, if you ask for one

The deadline≤ 20 days after finalisation

Where it is writtenImplementing Regulation, Article 11

Whose it isThe developer has to request it; the meeting is with the subgroup.

StepThe first request reaches you

The deadlineAfter the scope is finalised; its submission deadline may fall no later than 45 days before the envisaged CHMP opinion

Where it is writtenHTA Regulation, Article 10(1)

Whose it isThe Commission. This is the day the 100 days start.

StepThe dossier

The deadline100 days — or 60

Where it is writtenImplementing Regulation, Article 12(2)

Whose it isThe developer. 60 days under the accelerated procedure and for a new-indication variation.

StepThe Commission confirms completeness

The deadline15 working days, or 10

Where it is writtenImplementing Regulation, Article 13

Whose it isThe Commission, consulting the assessor and co-assessor as appropriate.

StepAnswer to a second request

The deadline15 days, or 10 — 7 if only minor information is missing

Where it is writtenImplementing Regulation, Article 12(4)

Whose it isThe developer. This is the last chance before discontinuation becomes possible.

StepAnswer to an assessor clarification

The deadlineBetween 7 and 30 days, set case by case

Where it is writtenImplementing Regulation, Article 12(5)

Whose it isThe developer. The assessor and co-assessor set the length by what is asked.

StepFactual accuracy and confidentiality on the revised draft report

The deadline7 days, or 5

Where it is writtenImplementing Regulation, Article 14(4)

Whose it isThe developer — technical and factual inaccuracies and confidentiality claims only.

StepThe subgroup finalises the revised draft reports

The deadlineAt the latest on the day the marketing authorisation decision is adopted

Where it is writtenImplementing Regulation, Article 15(2)

Whose it isThe subgroup.

StepThe Coordination Group endorses

The deadline≤ 30 days after the marketing authorisation decision

Where it is writtenHTA Regulation, Article 11(1)(a)

Whose it isThe Coordination Group, by consensus where it can reach one.

StepThe Commission’s procedural review

The deadline10 working days to object

Where it is writtenHTA Regulation, Article 12(3)

Whose it isThe Commission, then publication on the IT platform.

Deadlines in calendar days unless the rule says working days. The three shortened variants — 60 days for the dossier, 10 working days for the confirmation, 5 days for the factual accuracy check — apply in the same two cases: an application assessed under the accelerated procedure, and an assessment of a variation that corresponds to a new therapeutic indication.Source: HTA Regulation; Implementing Regulation (EU) 2024/1381

The clock that sets all the others: the EMA centralised procedure

Almost nothing in the list above is a date. They are offsets, and the things they are measured from belong to the marketing authorisation procedure: the day EMA validates the application, the day the Committee for Medicinal Products for Human Use adopts its list of questions, the envisaged date of the CHMP opinion, the day the Commission adopts the decision granting the authorisation.

Three of those offsets do the structural work. The scope must be finalised "at the latest 10 days after the Committee for Medicinal Products for Human Use adopts its list of questions". The dossier deadline set in the Commission's first request — the request that starts the dossier window — must fall "at the latest 45 days prior to the envisaged date of the opinion of the Committee for Medicinal Products for Human Use". And the Coordination Group must endorse the reports "no later than 30 days following the adoption of a Commission decision granting a marketing authorisation".

The practical consequence is that a slip in the regulatory procedure moves the HTA calendar with it, in both directions, and that a developer planning a joint clinical assessment is planning against its own regulatory team's forecast of a CHMP date. That forecast is the single most load-bearing assumption in the plan, and it is not under the HTA team's control. A team that treats the 100 days as a window it can place wherever it likes is planning against a date that nobody has promised it.

There is one more consequence worth saying out loud: the scope is finalised before the CHMP opinion, so the scope is written against the claimed indication and can be overtaken by the regulatory outcome. That is not an edge case — it has already happened in two of the four published assessments.

The 100 days, and the two cases where it is 60

The dossier deadline is the clearest sentence in the whole procedure: "the deadline to submit the dossier referred to in paragraph 1 shall be 100 days from the date of the notification of the first request to the health technology developer." It is measured from notification, not from receipt, and not from the day the team finishes reading the scope.

Two cases shorten it to 60. The first is an application assessed under the accelerated procedure of Article 14(9) of Regulation (EC) No 726/2004. The second is an assessment conducted for a variation to an existing marketing authorisation of the type in point 2(a) of Annex II to Regulation (EC) No 1234/2008 that corresponds to a new therapeutic indication — in everyday language, a Type II indication variation on a product that already has a published joint clinical assessment report.

The 100-day case and the 60-day case, side by side

The standard caseAccelerated assessment, or a new-indication variation
The dossier

The standard case: 100 days from notification of the first request.

Accelerated assessment, or a new-indication variation: 60 days — forty fewer, on a submission of the same size.

The scope is finalised

The standard case: At the latest 10 days after CHMP adopts its list of questions.

Accelerated assessment, or a new-indication variation: Within 75 days of EMA validating the application or the variation.

The Commission’s completeness check

The standard case: 15 working days from submission.

Accelerated assessment, or a new-indication variation: 10 working days.

Answering a second request

The standard case: 15 days — 7 where only minor information is missing.

Accelerated assessment, or a new-indication variation: 10 days — still 7 where only minor information is missing.

Factual accuracy on the revised draft report

The standard case: 7 days from receipt.

Accelerated assessment, or a new-indication variation: 5 days. The same 5 days apply where a new assessment scope was developed during the assessment.

What this means for the plan

The standard case: The evidence work can run partly in parallel with the scope being finalised.

Accelerated assessment, or a new-indication variation: Almost everything has to be ready before the scope arrives, because 60 days is not long enough to start an indirect comparison from nothing.

Drawn from Articles 10(2), 12(2), 12(4), 13 and 14(4) of Implementing Regulation (EU) 2024/1381. The last row is our reading, not a rule.Source: Implementing Regulation (EU) 2024/1381

A team that has been through a scoping exercise once tends to describe the 60-day case in the same way: the comparison plans have to exist in draft before the questions arrive. That is also the published view from inside the industry — a 2026 analysis of the scoping process by authors employed by a medicine developer frames it as the central constraint: once scoping ends, the developer has only the 100 days — or 60 for a new-indication variation — to finish the dossier (D'Oca, Darquennes and colleagues, 2026). Modelling the questions before the scope lands is the only lever that moves.

Can the 100-day deadline be extended?

Yes, narrowly, and not on request as a matter of course. "In justified cases, with the consent of the assessor and co-assessor and considering the timetable for the evaluation during the centralised procedure, the HTA secretariat may extend the deadline referred to in paragraph 2. However, that extension shall not exceed the deadline specified in Article 10(1) of Regulation (EU) 2021/2282."

That ceiling is the important half of the sentence. Article 10(1) puts the submission at the latest 45 days before the envisaged CHMP opinion, so an extension can only ever use up slack that exists between the end of the 100 days and that backstop. If the first request went out at the last possible moment, there is no slack to extend into, whatever the justification. An extension is therefore a function of how early the Commission's request happened to land, not of how good the reason is.

The failure mode at the other end is worth knowing precisely, because it is the only true cliff in the procedure. If, after the second request, the Commission finds the dossier late or still short of what Article 9(2) to (4) requires, the Coordination Group must discontinue the assessment (HTA Regulation, Article 10(6)). Discontinuation is published on the IT platform with its reasons. And the protection in Article 13(1), point (d) — that Member States may not ask nationally for evidence already submitted at Union level — stops applying. A discontinued assessment does not simply delay the Union-level step; it returns the developer to answering the same questions country by country.

A discontinued assessment can be re-initiated, at the latest six months after the original submission deadline, once the Coordination Group has received the missing evidence through a Member State and the Commission has confirmed the requirements are met.

The Commission's completeness check, and the second request's 15 days

Submitting the dossier does not end the window; it starts a short, decisive one. The Commission has 15 working days from submission to confirm, on the information it has at that point and consulting the assessor and co-assessor where appropriate, whether the dossier satisfies Article 9(2), (3) and (4) of the HTA Regulation (Implementing Regulation, Article 13). Ten working days in the accelerated and new-indication cases.

If something is missing, the Commission issues a second request, and the answer is due "within 15 days from the date of notification" — 10 days in the accelerated and new-indication cases, and 7 days "for cases where only minor information is missing". Fifteen days is not enough time to run a new indirect comparison, which is the practical reason the completeness test should be applied internally before submission rather than discovered afterwards.

The published reports show how real this is. Lurbinectedin's dossier went through version 0.1 on 16 December 2025, version 0.2 on 2 February 2026 and version 0.3 on 18 February 2026, both marked in the report's procedural table as responses to the second request, with the Commission's confirmation following on 23 February. Tovorafenib and tarlatamab each filed a second version before confirmation and a third afterwards. Not one of the four was confirmed on its first version.

Days from the scope arriving to dossier version 0.1, in the four published assessments

Lurbinectedin · 8 Sep to 16 Dec 2025
99 days
Tarlatamab · 29 Sep 2025 to 6 Jan 2026
99 days
Onasemnogene abeparvovec · 8 Sep to 17 Dec 2025
100 days
Tovorafenib · 6 Jun to 15 Sep 2025
101 days
Counted between the two rows every report prints: assessment scope shared with the developer, and dossier submission version 0.1. The statutory 100 days run from notification of the Commission's first request rather than from the scope being shared, which is why the counts land either side of 100. What they show is that every one of the four used the whole window.Source: Lurbinectedin; Tarlatamab; Onasemnogene abeparvovec; Tovorafenib

Seven days for the factual accuracy check — and what you may say in them

The developer sees the revised draft reports once, with a deadline measured in days and a scope measured in words. "The health technology developer shall signal any purely technical or factual inaccuracies and any information it considers to be confidential within 7 days from the date on which it received the revised draft joint clinical assessment and summary reports" — five days in the accelerated and new-indication cases, and also where a new assessment scope was developed during the assessment.

Two constraints ride with that deadline. Confidentiality is not asserted but demonstrated: the developer "shall demonstrate the commercially sensitive nature of the information it considers to be confidential". And the HTA Regulation removes the obvious temptation in a single line, which forbids the developer any comment on the results of the draft assessment (Article 11(5)).

So the seven days are for arithmetic, citations, mislabelled populations, a wrong data cut-off, a figure transposed between tables — not for arguing that an effect was understated. A team that wants those seven days to be usable has to be able to find, for any number in the draft report, the table in its own dossier it came from, in minutes rather than days. That is a filing problem solved long before the draft arrives, and it is the same discipline the dossier template itself demands, where every analysis has to be traceable to the documentation in Appendix D.

Endorsement: 30 days after the marketing authorisation decision

The end of the procedure is pinned to the regulatory decision, not to the assessment's own progress. The subgroup must finalise the revised draft reports "at the latest on the date of the adoption of the Commission decision granting the marketing authorisation", and the Coordination Group must endorse them "no later than 30 days following the adoption of a Commission decision granting a marketing authorisation".

Endorsement is by consensus where consensus exists. Where it does not, the Regulation does not stall: "where a consensus cannot be reached, divergent scientific opinions, including the scientific grounds on which those opinions are based, shall be incorporated in the reports and the reports shall be deemed endorsed." The Commission then has 10 working days to object on procedural grounds and ask for a review, and publishes once the reports are procedurally compliant.

The first report shows the shape in practice: the Commission granted the conditional marketing authorisation on 20 April 2026, the Coordination Group endorsed the report on 30 April, the Commission completed its procedural review on 19 May, and publication followed on 9 June. Ten days from decision to endorsement; a further forty to publication.

Two assessments end to end, drawn to the same scale

Tovorafenib · 11 Mar 2025 to 30 Apr 2026415 days
Scoping87 days
The dossier window101 days
Assessment to endorsement227 days
  • Scoping87 days
  • The dossier window101 days
  • Assessment to endorsement227 days
Tarlatamab · 11 Jul 2025 to 22 Jun 2026346 days
Scoping80 days
The dossier window99 days
Assessment to endorsement167 days
  • Scoping80 days
  • The dossier window99 days
  • Assessment to endorsement167 days
Counted from each report's own table of procedural steps; scoping runs from the first information submitted for the scope to the day the scope reached the developer. The middle phase is the only one with a statutory length and the only one the developer controls; in both assessments it is far shorter than the assessment phase that follows it. The difference between the two lanes is almost entirely in the last phase, which belongs to the assessors.Source: Tovorafenib report, Table 2; Tarlatamab report, Table 2

What the first four published assessments actually measured

Put the four together and three patterns show up, none of which is visible from the legal texts.

The developer's window is used in full, every time. Ninety-nine, ninety-nine, one hundred and one hundred and one days from the scope being shared to the first dossier version. Nobody submitted early. Whatever a plan says about an internal buffer, the observed behaviour of four teams at four companies is that the whole window gets used.

Nobody was confirmed on the first version. Each of the four filed at least one further version before the Commission's confirmation. Treat version 0.2 as part of the plan rather than as a failure.

The long pole is the assessment, and it is not yours. From dossier to endorsement took 167, 188, 211 and 227 days. That phase is the longest of the three in all four assessments, it varies by two months between them, and no amount of internal effort shortens it. A launch plan that assumes a fixed interval from submission to a published report is assuming something the record does not support.

The clock against the work, not beside it

The PICO grid of EU Joint Clinical Assessment with its countdown: the days left to submit on the HTA IT platform, the due date, each question's next dated step with its owner, and a banner naming the next milestone — comparison plans signed off — with the number of days until it falls due.
EU Joint Clinical Assessment on its sample assessment (demo). The useful unit is not the submission date but the next decision: a comparison plan that slips takes the result and the section that reports it with it, so the countdown sits on the row rather than on the cover.

The dates nobody plans for: a change of indication, and a re-initiated assessment

Two sequences sit outside the main chain, and both have already happened.

The first is a change of therapeutic indication during the centralised procedure. The assessor judges whether the change affects the scope and the subgroup decides whether the assessment continues or a new scope proposal is prepared; where a new scope is finalised, the developer is asked for an updated dossier under a deadline the assessors set between 7 and 30 days. In the onasemnogene abeparvovec assessment the developer notified a narrowed indication on 26 February 2026, a revised scope issued on 9 March, and dossier versions 0.3 and 0.4 followed on 10 and 19 March — two submissions in ten days, nearly three months after the original dossier. In the tovorafenib assessment the indication also changed and the subgroup decided no new scope was needed.

The second is a re-initiated or updated assessment. Where the Coordination Group re-initiates an assessment, or initiates an update and no change to the scope is needed, the subgroup finalises the revised draft reports within 180 days; where the scope also has to be updated, within 330 days. Those are year-scale commitments, and they attach to a product that is already on the market.

Five dates to put in the plan the day a product is confirmed in scope

  1. The envisaged CHMP opinion date, and who owns the forecast

    Every other date is measured from it. Name the person in regulatory affairs who updates it, and how often.

  2. The latest possible submission date: 45 days before that opinion

    That is the backstop the first request has to respect. The request usually comes early enough that the 100 days end before it; the gap between the two is the only slack an extension could ever use.

  3. Scope finalisation, and the 20 days that follow it

    The explanation meeting has to happen within 20 days of finalisation and has to be requested. Write the request before the scope lands.

  4. Submission day, and the 15 working days after it

    The Commission’s confirmation window. Hold the statistical capacity that would answer a second request in 15 days; do not release it at submission.

  5. The seven days on the revised draft report

    Diarise a traceability rehearsal before then: for any number in the draft, find the table in your dossier it came from.

Our planning checklist, built from the deadlines in Regulation (EU) 2021/2282 and Implementing Regulation (EU) 2024/1381. The dates themselves are statutory; the order in which a team should fix them is our suggestion.

A clock a team can set, inside a clock it cannot

The settings screen of EU Joint Clinical Assessment: the dossier window and its internal milestones — the day comparison plans are signed off, the day a full draft is due, the day of final sign-off — the sign-off chain naming who recommends and who approves, the evidence rules, and the reminders.
EU Joint Clinical Assessment on its sample assessment (demo). The statutory clock is 100 days, or 60 in the accelerated and new-indication cases; the milestones inside it — when comparison plans must be signed off, when a full draft is due — are a team's own and are configuration here, not code.

Questions people ask

How long do you have to submit a JCA dossier?

100 days from the date the Commission's first request is notified to you. It is 60 days where the marketing authorisation application is assessed under the accelerated procedure, and where the assessment concerns a variation corresponding to a new therapeutic indication on a product that already has a published report.

How long does the Commission take to confirm a JCA dossier?

Within 15 working days of submission, the Commission confirms whether the dossier meets Article 9(2), (3) and (4) of the HTA Regulation — 10 working days in the accelerated and new-indication cases. None of the first four published assessments was confirmed on its first dossier version; each filed at least one further version first.

How long do you get to answer a second request?

15 days from notification, or 10 in the accelerated and new-indication cases, and 7 days where only minor information is missing. It is the last step before the Coordination Group may discontinue the assessment, so plan for it rather than hoping to avoid it.

Can the JCA dossier deadline be extended?

In justified cases, with the consent of the assessor and co-assessor, the HTA secretariat may extend it — but never beyond 45 days before the envisaged CHMP opinion. In practice the available extension is whatever slack exists between the end of your 100 days and that backstop, which depends on how early the first request was sent.

When is the JCA report endorsed?

No later than 30 days after the Commission adopts the decision granting the marketing authorisation. The subgroup must have finalised the revised drafts by the day of that decision. The Commission then has 10 working days to raise a procedural objection, and publishes afterwards: for the first report, authorisation on 20 April 2026, endorsement on 30 April, procedural review on 19 May and publication on 9 June.

How long does a whole joint clinical assessment take?

The four published assessments ran 346 to 436 days from the first information submitted for the scope to endorsement. The dossier window is about a quarter of that; the phase from dossier to endorsement took between 167 and 227 days and belongs entirely to the assessors and the Coordination Group.

EU Joint Clinical Assessment.
See it on your own files.

An agentic solution from Botminds. Turns the EU assessment scope into a PICO grid (evidence, gaps, the section that answers each PICO and its next step on the 100-day clock) and drafts the cited dossier. Book a demo, or explore how it works.